Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Acadia Pharmaceuticals Earnings Call: Key Takeaways

Acadia delivered strong Q3 results with 22% revenue growth, raised DAYBUE guidance, and optimized its Phase 3 ADP program despite a Phase 2 primary endpoint miss, supported by a $976 million cash position.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthDAYBUE grew 39% to $140M; NUPLAZID grew 12% to $202M.
Mgmt ConfidenceHigh conviction in 60mg dose for ADP despite Phase 2 miss.
Demand VisibilityOver 50% of US DAYBUE patients switched to sticks formulation.
Margin TrendsDAYBUE gross-to-net 23.2%; NUPLAZID gross-to-net 22.7% in Q3.
Op. LeverageR&D expenses decreased to $76M from $88M year-over-year.
Pricing PowerGermany launch allows initial set price during reimbursement negotiations.
Vol vs PriceDAYBUE growth driven almost entirely by volume; NUPLAZID 11% volume growth.
Segment GrowthDAYBUE sticks driving restarts; NUPLAZID field force expansion doubling reach.
New ClientsNUPLAZID field force now engaging over 10,000 physicians.
Capex & DebtCash position of $976 million; no debt mentioned.
RegulatoryReceived US PTO notice of allowance for patent extending protection to 2041.
CommentaryStrategic shift to 60mg dose and central raters for Phase 3.
New LaunchesDAYBUE launched in Germany October 2026; sticks formulation driving growth.

Growth

Total revenue $342M (up 22%); DAYBUE $140M (up 39%); NUPLAZID $202M (up 12%).

Outlook

Raised 2026 DAYBUE guidance to $505M-$520M; $700M DAYBUE and $1B NUPLAZID targets by 2028.

Risks

Phase 2 Radiant study narrowly missed statistical significance (p=0.0603) on the primary endpoint.

Source

The company's earnings call, NASDAQ: ACAD, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Acadia Pharmaceuticals Inc: key numbers

Share price
$18.67Close, Nov 16
Market cap
$3.23B
Shares outstanding
172.83MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Acadia Pharmaceuticals Inc

All →
6:02 AM ET 10-Q
Financial Results ▶ Call

Acadia Pharmaceuticals Q3 2026 Results: Net Income $53.5M, Down 25.4% YoY

ACADIA Pharmaceuticals reported strong revenue growth driven by its commercial products, NUPLAZID and DAYBUE, alongside disciplined management of operating expenses. The company continues to invest in its late-stage clinical pipeline while showing significant progress toward sustained profitability.

Key figure
Net income $53.5M · -25.4% YoY
4:14 PM ET 8-K
Financial Results

Acadia Pharmaceuticals Financial Results

Acadia Pharmaceuticals reported Q3 2026 total revenues of $342 million, a 22% increase year-over-year, driven by strong sales of DAYBUE and NUPLAZID. The company raised its 2026 net sales guidance for DAYBUE to $505–$520 million and highlighted upcoming Phase 2 readouts for its pipeline candidates in 2027.

Term
Q3 2026

“Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID. In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build momentum following our recent launch of DAYBU in Germany. NUPLAZID also performed well, driven by underlying demand and the continued expansion of our commercial reach.”

Catherine Owen Adams, Chief Executive Officer of Acadia
8:21 PM ET Form 4
Insider Selling

Acadia Pharmaceuticals EVP, CFO Mark C. Schneyer Sells $69.3K of Stock

Mark C. Schneyer, EVP, CFO, sold 3,321 shares of Acadia Pharmaceuticals Inc at $20.88 a share, worth $69.3K in total on Oct 30, 2026. Shares held after the trade: 71,322 (-4.4%).

Value
$69.3K
Shares
3,321
Price
$20.88
Role
EVP, CFO
Holding change
-4.4%
Trade date
Oct 30, 2026
4:53 PM ET 8-K
Leadership Change

Acadia Pharmaceuticals Leadership Change

Elizabeth H.Z. Thompson, Ph.D., has stepped down from her role as Executive Vice President and Head of Research and Development at Acadia Pharmaceuticals effective October 23, 2026. Dr. Thompson will transition to a consulting role through December 31, 2026, while the company continues its search for a permanent replacement.

Term
through Dec 2026
5:11 PM ET 8-K
Clinical Trial Data

Acadia Pharmaceuticals Clinical Trial Data

Acadia Pharmaceuticals announced Phase 3 enabling topline results from the Phase 2 portion of its RADIANT trial evaluating remlifanserin for Alzheimer’s disease psychosis (ADP). While the 60 mg dose narrowly missed the primary endpoint (p=0.0603), it showed nominal significance on a key secondary endpoint and a favorable safety profile, leading the company to continue its Phase 3 program with the 60 mg dose.

Earnings call
Sep 24, 2026, 8:00 AM ET
9:09 AM ET 8-K
Court & Legal Update

Acadia Pharmaceuticals Court & Legal Update

The U.S. District Court for the Southern District of California has granted preliminary approval for a settlement of a stockholder derivative action against Acadia Pharmaceuticals and certain of its officers and directors. The settlement resolves claims related to the company's drug pimavanserin (NUPLAZID) and includes the implementation of corporate governance reforms and the payment of plaintiff attorney fees. A final settlement hearing is scheduled for January 13, 2027.

Counterparty
Kanner et al.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.